Clinical Trial Update: Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis [Phase 2]

View source ↗

Summary

A Phase II trial testing moderate-dose hypofractionated radiotherapy plus tislelizumab for hepatocellular carcinoma with diffuse tumor thrombosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Hepatocellular Carcinoma, Radiotherapy | Phase 2 | Status: COMPLETED